Mimicking Slipping Responses Using a Novel Mechanical Perturbation Algorithm
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Linard Filli, Dr.
- Phone Number: +41 44 510 72 12
- Email: linard.filli@balgrist.ch
Study Contact Backup
- Name: Marina Geissmann, MSc
- Phone Number: +41 44 510 74 14
- Email: marina.geissmann@balgrist.ch
Study Locations
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Switzerland, 8008
- Balgrist Campus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy subjects aged 18-40 years and 60-80 years
- Ability to walk at minimum 30 minutes at a regular pace without assistance or breaks
- Written informed consent as documented by signature (see informed consent form)
Exclusion Criteria:
- Women who are pregnant or breast feeding
- Current neurological problems affecting walking function and balance
- Current orthopedic problems affecting upper and lower extremity movements
- History of alcohol abuse or the intake of psychotropic drugs
- History of major cardiac condition (e.g., infarction, insufficiency (NYHA II-IV))
- History of major pulmonary condition (e.g., chronic obstructive pulmonary disease (GOLD II-IV))
- Current major depression or psychosis
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia
- Fever of unknown origin
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy participants between 18 and 40 years of age
|
Acceleration or deacceleration of one treadmill gait belt.
|
|
Healthy participants between 60 and 80 years of age
|
Acceleration or deacceleration of one treadmill gait belt.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calculation of Margins of Stability (MoS) in anterior-posterior direction at foot contact
Time Frame: Once during visit 1
|
Difference between base of support and interpolated center of mass (mm), based on 3D motion capture.
|
Once during visit 1
|
|
Step length at baseline, before (Pre) and after (Recovery step 1-10) perturbation
Time Frame: Once during visit 1
|
Once during visit 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Step width at foot contact of baseline, before (Pre) and Recovery steps 1-10
Time Frame: Once during visit 1
|
Once during visit 1
|
|
|
Calculation of Margin of stability medial-lateral direction at foot contact of baseline, before (Pre) and Recovery steps 1-10
Time Frame: Once during visit 1
|
Difference between base of support and interpolated center of mass (mm), based on 3D motion capture.
|
Once during visit 1
|
|
Maximal trunk velocity during gait cycle at of baseline, before (Pre) and Recovery steps 1-10 to detect fast trunk movement to gain balance
Time Frame: Once during visit 1
|
Optical markers are placed on the upper body of the subjects and will be used for calculation (distance over time) of the trunk velocity.
|
Once during visit 1
|
|
3D kinematic gait profiles to analyze detailed movement patterns/strategies
Time Frame: Once during visit 1
|
The optical markers are placed according to the Plug-in gait marker set in Vicon Nexus (motion capture system).
Hip, knee, ankle and trunk angles are calculated from this marker set.
|
Once during visit 1
|
|
EMG analysis to detect reaction time and activity patterns of different leg muscles
Time Frame: Once during visit 1
|
Once during visit 1
|
|
|
Questionnaire regarding the incidence of falls in the last six months
Time Frame: Once during visit 1
|
Contains questions how often und the reason why the subject falls
|
Once during visit 1
|
|
Activities specific Balance Confidence scale (ABC scale)
Time Frame: Once during visit 1
|
Contains 16 questions rating the balance confidence between 0-100%.
100% means absolutely confident in doing some activity
|
Once during visit 1
|
|
Questionnaire regarding the perceived intensities of the three perturbation algorithms
Time Frame: Once during visit 1
|
Judging the three pertubation algorithms according to their intensity, inconvenience and how realistic the slipping felt.
Scale ranges from 0-10, whereas 10 is the most intense
|
Once during visit 1
|
|
Functional Gait Assessment (FGA) as a clinical balance test
Time Frame: Once during visit 1
|
Assess the dynamic stability during different walking tasks.
In total, 30 points are possible, at 22 points is the cut off score to classify the fall risk in older adults in predicting falls.
|
Once during visit 1
|
|
A set of kinematic parameters
Time Frame: Once during visit 1
|
Measurement of hip, knee, ankle and spine angles during walking in degrees (°).
|
Once during visit 1
|
|
A set of kinetic parameters
Time Frame: Once during visit 1
|
Ground reaction forces measured by force plates in Newton (N).
|
Once during visit 1
|
|
A set of spatiotemporal parameters
Time Frame: Once during visit 1
|
Stance time, double stance time in seconds (s).
|
Once during visit 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Linard Filli, Dr., University of Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-00213
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.